For patients with neovascular age-related macular degeneration (nAMD), ranibizumab with a port delivery system (PDS) with one refill costs more than intravitreal ranibizumab or aflibercept injections if about 11 or 10 injections, respectively, or fewer are needed within the first year, according to a study published online June 16 in JAMA Ophthalmology.
Cost of ranibizumab port delivery system for treating nAMD examined
-
SecurityPrivacy violations undermine the trustworthiness of the Tim Hortons brand
-
Featured HeadlinesWhy Tesla’s Autopilot crashes spurred the feds to investigate driver-assist technologies – and what that means for the future of self-driving cars
-
InternetRegulating online hate will have unintended, but predictable, consequences
-
Featured HeadlinesBeyond a technical bug: Biased algorithms and moderation are censoring activists on social media
-
Featured HeadlinesGovernment agencies are tapping a facial recognition company to prove you’re you – here’s why that raises concerns about privacy, accuracy and fairness
-
Featured HeadlinesTech giants need to step up to help close Canada’s digital divide
